Lineage Cell Therapeutics, Inc.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $14.6M | $9.5M | $8.9M | $14.7M | $4.3M |
| Cost of revenue | — | $334,000 | $671,000 | $728,000 | $1.4M |
| Gross profit | — | — | $8.3M | $14.0M | $2.9M |
| Research and development | $17.7M | $12.5M | $15.7M | $14.0M | $33.9M |
| Operating expenses | — | — | $33.0M | $36.5M | $52.1M |
| Operating income | -$36.6M | -$21.5M | -$24.7M | -$22.5M | -$49.2M |
| Pretax income | -$68.6M | -$18.6M | -$23.3M | -$25.8M | -$43.3M |
| Income tax expense | -$5.3M | $0 | -$1.8M | $541,000 | — |
| Net income | -$63.5M | -$18.6M | -$21.5M | -$26.3M | -$43.0M |
| Balance Sheet | |||||
| Cash and equivalents | $40.8M | $45.8M | $35.4M | $11.4M | $55.7M |
| Current assets | $59.2M | $51.0M | $38.4M | $60.0M | $111.5M |
| Total assets | $112.6M | $113.2M | $101.0M | $123.7M | $174.5M |
| Current liabilities | $11.4M | $14.0M | $18.0M | $19.0M | $47.1M |
| Total liabilities | $69.2M | $36.2M | $39.0M | $51.7M | $83.6M |
| Stockholders' equity | $44.5M | $78.4M | $63.4M | $73.3M | $92.2M |
| Cash Flow Statement | |||||
| Cash from operations | -$18.9M | -$23.1M | -$28.6M | $1.1M | -$23.6M |
| Depreciation and amortization | $699,000 | $587,000 | $562,000 | $582,000 | $663,000 |
| Stock-based compensation | $4.8M | $5.1M | $4.6M | $4.3M | $3.5M |
| Capital expenditure | $522,000 | $565,000 | $674,000 | $413,000 | $340,000 |
| Free cash flow | -$19.4M | -$23.7M | -$29.2M | $646,000 | -$23.9M |
| Impairments | $14.8M | $0 | $0 | $0 | — |
Shares outstanding 249.3M · Free float 45.4%
Annual filing data through FY ended December 31, 2025; float as of July 11, 2026.